Search results
U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND...
The Sun Chronicle· 7 days agoIf approved, the investigational therapy would offer a new treatment option for patients with advanced gastric and gastroesophageal junction cancers as the first and only CLDN18.2-targeted therapy ...
Moffitt Cancer Center and Virogen Biotechnology Fo | Newswise
Newswise· 7 days agoTAMPA, Fla., and PLEASANTON, Calif. — Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Virogen Biotechnology Inc., a clinical-stage biotechnology company, announced ...
TECVAYLI® (teclistamab-cqyv) shows sustained deep and durable responses in patients with relapsed or...
Valley City Times Record· 4 days ago"With the longest follow-up of any bispecific antibody, teclistamab demonstrates continued deep and durable responses observed in patients with relapsed or refractory multiple myeloma who have ...
Small Business - Austin Daily Herald | Austin Daily Herald
Austin Daily Herald· 7 days agoU.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE PR Newswire TOKYO, May 30, 2024 If approved, the investigational therapy would offer a new treatment option for patients with
